JP2019504877A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504877A5 JP2019504877A5 JP2018553042A JP2018553042A JP2019504877A5 JP 2019504877 A5 JP2019504877 A5 JP 2019504877A5 JP 2018553042 A JP2018553042 A JP 2018553042A JP 2018553042 A JP2018553042 A JP 2018553042A JP 2019504877 A5 JP2019504877 A5 JP 2019504877A5
- Authority
- JP
- Japan
- Prior art keywords
- particles
- composition
- carrier
- antigens
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 claims 30
- 239000000427 antigen Substances 0.000 claims 14
- 102000038129 antigens Human genes 0.000 claims 12
- 108091007172 antigens Proteins 0.000 claims 12
- 239000000969 carrier Substances 0.000 claims 12
- 229920001983 poloxamer Polymers 0.000 claims 6
- AWWLEBBAQLFDFA-UHFFFAOYSA-N 1,4-bis(ethenyl)benzene;3-phenylpropanoic acid;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=C(C=C)C=C1.OC(=O)CCC1=CC=CC=C1 AWWLEBBAQLFDFA-UHFFFAOYSA-N 0.000 claims 3
- 229960000502 Poloxamer Drugs 0.000 claims 3
- 239000004743 Polypropylene Substances 0.000 claims 3
- 239000004793 Polystyrene Substances 0.000 claims 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 3
- -1 polypropylene Polymers 0.000 claims 3
- 229920001155 polypropylene Polymers 0.000 claims 3
- 229920002223 polystyrene Polymers 0.000 claims 3
- 150000003568 thioethers Chemical class 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 206010003816 Autoimmune disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010024579 Lysosomal storage disease Diseases 0.000 claims 1
- 208000008425 Protein Deficiency Diseases 0.000 claims 1
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 230000002009 allergen Effects 0.000 claims 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 238000007334 copolymerization reaction Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 238000002641 enzyme replacement therapy Methods 0.000 claims 1
- 230000000521 hyperimmunizing Effects 0.000 claims 1
- 200000000018 inflammatory disease Diseases 0.000 claims 1
- 238000009163 protein therapy Methods 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 210000001519 tissues Anatomy 0.000 claims 1
Claims (16)
- 負のゼータ電位を有する担体粒子に共有結合した1又は複数の抗原を含む組成物であって、前記1又は複数の抗原が前記粒子中に封入されている、組成物。
- 前記1又は複数の抗原が、前記担体粒子の内部表面に共有結合している、請求項1に記載の組成物。
- 前記粒子のゼータ電位が約−100mV未満である、請求項1又は2に記載の組成物。
- 前記粒子が約50:50、80:20から約100:0のモル比を有するポリマー又はコポリマーを含む、請求項1から3のいずれか一項に記載の組成物。
- 前記粒子が、ポリスチレン粒子、カルボキシル化ポリスチレン粒子、PLURONIC(登録商標)安定化ポリプロピレンスルフィド粒子、ポロキサマー安定化担体粒子、又はポリ(乳酸−co−グリコール酸)粒子を含む、請求項1から4のいずれか一項に記載の組成物。
- 前記粒子が約0.1μmから約10μmの間の平均直径を有する、請求項1から5のいずれか一項に記載の組成物。
- 前記1又は複数の抗原が、自己免疫抗原、対象に移植される組織上に発現される抗原、酵素置換療法のための酵素、タンパク質療法、又はアレルゲンを含む、請求項1から6のいずれか一項に記載の組成物。
- 前記1又は複数の抗原が、前記担体粒子に直接的に共有結合している、請求項1から7のいずれか一項に記載の組成物。
- 対象において抗原特異的寛容を誘導する方法に使用するための、負のゼータ電位を有する担体粒子に共有結合した1又は複数の抗原を含む有効量の組成物であって、前記1又は複数の抗原が前記粒子中に封入されている、組成物。
- 前記疾患又は状態が、自己免疫疾患、リソソーム蓄積症、酵素欠損、炎症性疾患、アレルギー、移植拒絶、及び高度免疫応答からなる群から選択される、請求項9に記載の組成物。
- 前記担体粒子が、ポリスチレン粒子、カルボキシル化ポリスチレン粒子、PLURONIC(登録商標)安定化ポリプロピレンスルフィド粒子、ポロキサマー安定化担体粒子、又はポリ(乳酸−co−グリコール酸)粒子を含む、請求項9又は10に記載の組成物。
- 当該組成物が静脈内投与される、請求項9から11のいずれか一項に記載の組成物。
- 調節性T細胞を誘導する方法であって、前記T細胞を、請求項1に記載の組成物の有効量を用いて処理することを含む、方法に使用され、粒径が80nmより大きい、請求項1に記載の組成物。
- 負のゼータ電位を有する寛容化免疫改変粒子(TIMP)の調製のための方法であって、
a)1又は複数の担体ポリマーを、1又は複数の抗原と共有結合で連結して、担体ポリマー−抗原コンジュゲートを形成することと、
b)前記担体ポリマー−抗原コンジュゲートを、TIMPを形成するのに有効な条件下で溶液と接触させることと、
を含み、
負のゼータ電位を有する前記TIMPが形成され、前記1又は複数の抗原が前記TIMP中に封入される、
方法。 - 前記粒子が、ポリスチレン粒子、カルボキシル化ポリスチレン粒子、PLURONIC(登録商標)安定化ポリプロピレンスルフィド粒子、ポロキサマー安定化担体粒子、又はポリ(乳酸−co−グリコール酸)粒子を含む、請求項14に記載の方法。
- 前記担体ポリマーが、共重合によって形成される、請求項14又は15に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022125126A JP2022169597A (ja) | 2015-12-23 | 2022-08-04 | 共有ポリマー抗原コンジュゲート化粒子 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562387183P | 2015-12-23 | 2015-12-23 | |
US62/387,183 | 2015-12-23 | ||
US201662292098P | 2016-02-05 | 2016-02-05 | |
US62/292,098 | 2016-02-05 | ||
PCT/US2016/068423 WO2017112899A1 (en) | 2015-12-23 | 2016-12-22 | Covalent polymer-antigen conjugated particles |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022125126A Division JP2022169597A (ja) | 2015-12-23 | 2022-08-04 | 共有ポリマー抗原コンジュゲート化粒子 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019504877A JP2019504877A (ja) | 2019-02-21 |
JP2019504877A5 true JP2019504877A5 (ja) | 2020-02-06 |
JP7194593B2 JP7194593B2 (ja) | 2022-12-22 |
Family
ID=59091248
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018553042A Active JP7194593B2 (ja) | 2015-12-23 | 2016-12-22 | 共有ポリマー抗原コンジュゲート化粒子 |
JP2022125126A Pending JP2022169597A (ja) | 2015-12-23 | 2022-08-04 | 共有ポリマー抗原コンジュゲート化粒子 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022125126A Pending JP2022169597A (ja) | 2015-12-23 | 2022-08-04 | 共有ポリマー抗原コンジュゲート化粒子 |
Country Status (8)
Country | Link |
---|---|
US (2) | US11510996B2 (ja) |
EP (1) | EP3393514A4 (ja) |
JP (2) | JP7194593B2 (ja) |
KR (1) | KR20180101410A (ja) |
AU (1) | AU2016379413B2 (ja) |
CA (1) | CA3008892A1 (ja) |
IL (1) | IL260074A (ja) |
WO (1) | WO2017112899A1 (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
JP6017422B2 (ja) | 2010-08-10 | 2016-11-02 | エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ(ウペエフエル)Ecole Polytechnique Federale de Lausanne (EPFL) | 赤血球結合療法 |
US9597385B2 (en) | 2012-04-23 | 2017-03-21 | Allertein Therapeutics, Llc | Nanoparticles for treatment of allergy |
US9539217B2 (en) | 2013-04-03 | 2017-01-10 | Allertein Therapeutics, Llc | Nanoparticle compositions |
US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
NZ723879A (en) | 2014-02-21 | 2018-03-23 | Ecole Polytechnique Fed Lausanne Epfl | Glycotargeting therapeutics |
WO2018232176A1 (en) | 2017-06-16 | 2018-12-20 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
CN111867565A (zh) * | 2018-02-08 | 2020-10-30 | 库尔制药发展公司股份有限公司 | 使用耐受颗粒治疗乳糜泻 |
WO2019217780A1 (en) | 2018-05-11 | 2019-11-14 | Phosphorex, Inc. | Microparticles and nanoparticles having negative surface charges |
GB201913408D0 (en) * | 2019-09-17 | 2019-10-30 | King S College London | Proinsulin peptides for type 1 diabetes |
WO2022032290A2 (en) * | 2020-08-05 | 2022-02-10 | University Of Maryland, Baltimore | Engineering diverse antigen-presenting cells to control antigen-specific responses |
KR20230171998A (ko) | 2021-04-16 | 2023-12-21 | 코어 파마슈티칼스 디벨롭먼트 컴퍼니 인크. | 면역학적 관용의 유지를 추적하는 방법 |
WO2023070104A1 (en) | 2021-10-21 | 2023-04-27 | Cour Pharmaceuticals Development Company Inc. | Treatment of primary biliary cholangitis (pbc) with tolerizing nanoparticles |
TW202400801A (zh) | 2022-04-29 | 2024-01-01 | 美商庫爾製藥發展公司股份有限公司 | 用於克服治療性載體及蛋白質之免疫原性之耐受性免疫修飾奈米粒子 |
WO2024026452A1 (en) | 2022-07-29 | 2024-02-01 | Repertoire Immune Medicines, Inc. | T cell epitopes associated with type 1 diabetes |
WO2024086706A1 (en) | 2022-10-19 | 2024-04-25 | Cour Pharmaceuticals Development Company Inc. | Treatment of peanut allergy with tolerizing nanoparticles |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
BR9306042A (pt) | 1992-02-28 | 1997-11-18 | Autoimmune Inc | Método para tratar uma doença auto-immune em um mamifero e formas de dosagens farmacêuticas oral e inalável |
AU674584B2 (en) | 1993-06-02 | 1997-01-02 | Tvw Telethon Institute For Child Health Research | Cryptic peptides for use in inducing immunologic tolerance |
ATE249491T1 (de) | 1997-03-31 | 2003-09-15 | Univ Michigan | Offenporige bioabbaubare matrize |
US7427602B1 (en) | 1998-05-13 | 2008-09-23 | The Regents Of The University Of Michigan | Sustained DNA delivery from structural matrices |
US7029697B2 (en) | 2001-02-14 | 2006-04-18 | Northwestern University | Controlled surface-associated delivery of genes and oligonucleotides |
US6890556B1 (en) | 2001-02-14 | 2005-05-10 | Northwestern University | Controlled surface-associated delivery of genes and oligonucleotides |
US7846466B2 (en) | 2004-06-10 | 2010-12-07 | Northwestern University | Biodegradable scaffolds and uses thereof |
JP4933455B2 (ja) | 2005-02-02 | 2012-05-16 | ノヴォ ノルディスク アー/エス | 新規のインスリン誘導体 |
EP2630967A1 (en) | 2007-10-12 | 2013-08-28 | Massachusetts Institute of Technology | Vaccine nanotechnology |
US20090238879A1 (en) | 2008-01-24 | 2009-09-24 | Northwestern University | Delivery scaffolds and related methods of use |
US8343498B2 (en) * | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
CA3042826A1 (en) | 2008-11-30 | 2010-06-03 | Immusant, Inc. | Compositions and methods for treatment of celiac disease |
JP2012515722A (ja) | 2009-01-20 | 2012-07-12 | ノースウェスタン ユニバーシティ | 抗原特異的寛容の誘導のための組成物および方法 |
WO2013192532A2 (en) | 2012-06-21 | 2013-12-27 | Northwestern University | Peptide conjugated particles |
SI3033102T2 (sl) | 2013-08-13 | 2024-03-29 | Northwestern University | Peptid konjugirani delci |
-
2016
- 2016-12-22 JP JP2018553042A patent/JP7194593B2/ja active Active
- 2016-12-22 AU AU2016379413A patent/AU2016379413B2/en active Active
- 2016-12-22 CA CA3008892A patent/CA3008892A1/en active Pending
- 2016-12-22 KR KR1020187020952A patent/KR20180101410A/ko unknown
- 2016-12-22 US US16/064,528 patent/US11510996B2/en active Active
- 2016-12-22 WO PCT/US2016/068423 patent/WO2017112899A1/en active Application Filing
- 2016-12-22 EP EP16880118.1A patent/EP3393514A4/en active Pending
-
2018
- 2018-06-17 IL IL260074A patent/IL260074A/en unknown
-
2022
- 2022-08-04 JP JP2022125126A patent/JP2022169597A/ja active Pending
- 2022-10-24 US US18/049,136 patent/US20230338576A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019504877A5 (ja) | ||
Drachuk et al. | pH-responsive layer-by-layer nanoshells for direct regulation of cell activity | |
Fang et al. | Nanoparticle-based modulation of the immune system | |
Li et al. | Zwitterionic biomaterials | |
Tomaro-Duchesneau et al. | Microencapsulation for the therapeutic delivery of drugs, live mammalian and bacterial cells, and other biopharmaceutics: current status and future directions | |
Cu et al. | Controlled surface modification with poly (ethylene) glycol enhances diffusion of PLGA nanoparticles in human cervical mucus | |
Pearson et al. | Controlled delivery of single or multiple antigens in tolerogenic nanoparticles using peptide-polymer bioconjugates | |
Xu et al. | Eudragit® L100-coated mannosylated chitosan nanoparticles for oral protein vaccine delivery | |
Liu et al. | Poly (N‐vinylcaprolactam): a thermoresponsive macromolecule with promising future in biomedical field | |
Zhou et al. | Novel zwitterionic vectors: Multi-functional delivery systems for therapeutic genes and drugs | |
Tang et al. | Physical hydrogels with self-assembled nanostructures as drug delivery systems | |
Wang et al. | More effective nanomedicines through particle design | |
Zheng et al. | Enhancement of surface graft density of MPEG on alginate/chitosan hydrogel microcapsules for protein repellency | |
Gattás-Asfura et al. | Bioorthogonal layer-by-layer encapsulation of pancreatic islets via hyperbranched polymers | |
Bami et al. | pH-responsive drug delivery systems as intelligent carriers for targeted drug therapy: Brief history, properties, synthesis, mechanism and application | |
Stead et al. | Murine and non-human primate dendritic cell targeting nanoparticles for in vivo generation of regulatory T-cells | |
US20070154397A1 (en) | Thermosensitive nanostructure for hyperthermia treatment | |
JP2018503736A5 (ja) | ||
Giovagnoli et al. | Alginates in pharmaceutics and biomedicine: is the future so bright? | |
Hlídková et al. | Antifouling peptide dendrimer surface of monodisperse magnetic poly (glycidyl methacrylate) microspheres | |
Lu et al. | Preparation and characterization of molecularly imprinted poly (hydroxyethyl methacrylate) microspheres for sustained release of gatifloxacin | |
RU2016149734A (ru) | Направленно доставляемые терапевтические наночастицы и способы их получения и использования | |
Vorobii et al. | Antifouling microparticles to scavenge lipopolysaccharide from human blood plasma | |
Mudhakir et al. | Encapsulation of risperidone into chitosan-based nanocarrier via ionic binding interaction | |
CN101836970A (zh) | 一种聚丙烯酸纳米凝胶微球及其制法和用途 |